Agenus To Host BOT/BAL Program Update at ESMO 2023
05 Outubro 2023 - 8:30AM
Business Wire
Agenus Inc. (Nasdaq: AGEN), a leader in developing novel
immunological agents to treat various cancers, today announced that
the Company will host a corporate event to discuss advancements in
its botensilimab/balstilimab (BOT/BAL) program at the upcoming
European Society for Medical Oncology (ESMO) Conference on Sunday,
October 22, 2023. Agenus will provide updates from the ongoing
BOT/BAL clinical program, including in neoadjuvant colorectal
cancer and pancreatic cancer. A live webcast of the event will be
available.
Speakers include:
- Alexander Eggermont, M.D., Ph.D., University Medical Center,
Utrecht, Princess Maxima Center for Pediatric Oncology,
Comprehensive Cancer Center
- Marwan Fakih, M.D., City of Hope
- Manuel Hidalgo, M.D., Ph.D., Weill Cornell Medicine
- Pashtoon Kasi, M.D., M.S., Weill Cornell Medicine
- Breelyn Wilky, M.D., University of Colorado Medicine
- Steven O’Day, M.D., Chief Medical Officer, Agenus
- Todd Yancey, M.D., Senior Advisor, Agenus
Event Details
Date: Sunday, October 22, 2023
Time: 19:00 – 21:00 CEST (1:00 p.m. – 3:00 p.m. EDT)
To register for the webcast, please click here.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and
infectious diseases with a comprehensive pipeline of immunological
agents. The company’s mission is to expand patient populations
benefiting from cancer immunotherapy through combination
approaches, using a broad repertoire of antibody therapeutics,
adoptive cell therapies (through MiNK Therapeutics) and adjuvants
(through SaponiQx). Agenus is headquartered in Lexington, MA. For
more information, visit www.agenusbio.com or @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and Twitter.
Forward Looking
Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding a Agenus’s
corporate event at ESMO and related presentation about its
botensilimab programs and any other statements containing the words
"may," "believes," "expects," "anticipates," "hopes," "intends,"
"plans," "forecasts," "estimates," "will," “establish,”
“potential,” “superiority,” “best in class,” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include, among others, the factors
described under the Risk Factors section of our most recent
Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed
with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231005697057/en/
Investors 917-362-1370
investor@agenusbio.com
Media 781-674-4784
communications@agenusbio.com
Agenus (NASDAQ:AGEN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Agenus (NASDAQ:AGEN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024